A comparative clinical study of the Unani compound medical preparation for Antilipidaemic activity with special reference to the modern drug Atorvastatin

Abstract

Dyslipidaemia is a metabolic disorder. It is aa common problem iproblem in the global community today. It leads to Atherosclerosis, hypertension, ischaemic heart diseases and strokes. Hence this is a life threatening condition. Coronary Heart Disease (CHD) is the leading cause of morbidity and mortality in the United States, accounting for approximately 500,000 deaths per year and associated annual morbidity cost of more than $200 billion. In the past three-decades, numerous clinical and epidemiological studies have shown repeatedly that an elevated blood cholesterol level is one of the major modifiable risk factors associated with the development of CHD. In particular, these studies have demonstrated that low-density lipoprotein (LDL) cholesterol is the primary lipoprotein mediating atherosclerosis. Framingham Heart Study, population studies from Norway and Australia documented that hypertension was associated with increased levels of total cholesterol and a decreased levels of HDL cholesterol. It has been proved in U.S.A that if blood cholesterol is decreased to 25%; 49 % of heart disease will be reduced. This situation has increased gradually in Sri-Lanka has shown the reports of bulletin of medical research institute of Sri Lanka Volume - III 1987 and Volume -V in 1988/1989. Coronary heart disease resulting from progressive atherosclerosis remains the most common cause of morbidity and mortality all over the world (Yusuf et al. 2001). In developing countries, the incidence of cardiovascular disease is increasing alarmingly. India is on the verge of cardiovascular epidemics (Grover et al. 2003; Okrainec et al. 2004). The circulatory system disorders are going to be the greatest killer in India by the end of year 2015 (Kaul et al. 1998).